Don’t Delay With Delta: Best Practices and Calls to Action in HDV

Hear expert insights on the global burden and epidemiology of hepatitis delta virus (HDV) and the challenges associated with accurately diagnosing the population with HDV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: December 13, 2021 Expired: No longer available for credit

Hear expert insights on whom to test for hepatitis delta virus, how to test, and limitations of current testing options and approaches.

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: January 18, 2022 Expired: No longer available for credit

Hear patient insights on the delay in diagnosis and impact of living with hepatitis delta.

Joseph (Patient) Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: February 3, 2022 Expired: No longer available for credit

Hear expert insights on current treatments for HDV and the importance of developing new agents that are better tolerated and have improved efficacy.

Nancy Reau, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: March 7, 2022 Expired: No longer available for credit

Hear expert insights on the role in therapy of new and investigational treatments for patients with HDV.

Stefan Zeuzem, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: March 9, 2022 Expired: No longer available for credit

Hear expert insights on the role of advanced practice providers in the management of hepatitis delta virus infections, including medication monitoring and patient education.

Richard H. Davis, PA-C Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: March 2, 2022 Expired: No longer available for credit

Hepatitis delta is the most severe form of viral hepatitis, and many patients remain undiagnosed. Listen to experts discuss a call to action for universal screening of patients with hepatitis B for coinfection with hepatitis delta.

Maria Buti, MD Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: December 20, 2021 Expired: No longer available for credit

Few treatment options exist for HDV, but many promising investigational agents are on the horizon. Listen to experts discuss what questions still need to be answered to optimize treatment of HDV with current―as well as new and emerging―agents.

Nancy Reau, MD Stefan Zeuzem, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: March 3, 2022 Expired: No longer available for credit

The hepatitis delta virus (HDV) only coexists in patients chronically infected with hepatitis B virus (HBV). Listen to experts discuss steps to take for monitoring and treating both forms of viral hepatitis.

Heiner Wedemeyer, MD Cihan Yurdaydin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: March 10, 2022 Expired: No longer available for credit

Several emerging agents will soon be available for the treatment of hepatitis delta virus (HDV). Hear experts discuss rational use and combinations of new agents to treat patients with HDV.

Heiner Wedemeyer, MD Cihan Yurdaydin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: March 16, 2022 Expired: No longer available for credit

Listen as 2 experts discuss the importance of increasing healthcare professional and patient awareness of HDV to ensure that at-risk patients receive screening and then treatment and monitoring following a positive test.

Grace LH Wong, MD Ming-Lung Yu, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: May 3, 2022 Expired: No longer available for credit

Your patient tests positive for hepatitis delta virus (HDV). Now what? Listen as 2 experts discuss challenges and opportunities in linking patients with HDV to care.

Kosh Agarwal, MD Graham R. Foster, FRCP, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: June 30, 2022 Expired: No longer available for credit

Comprehensive slideset updated regularly to include the latest data and guideline updates for hepatitis delta virus (HDV).

Joseph (Patient) Maria Buti, MD Richard H. Davis, PA-C Robert G. Gish, MD Nancy Reau, MD Stefan Zeuzem, MD Released: July 25, 2022

To link patients with hepatitis delta virus to care, we first must be able to identify them.

Cihan Yurdaydin, MD Released: March 8, 2022

Emerging treatment options for hepatitis delta virus are promising, but we still have more questions than answers regarding the optimal use of these agents around the globe.

Heiner Wedemeyer, MD Released: March 23, 2022

My thinking about HDV testing recommendations has shifted in recent years. Here’s why.

Norah Terrault, MD, MPH Released: May 18, 2022

Our current treatment option for hepatitis delta virus is pegylated interferon alfa, which does not have robust efficacy data and is not always well tolerated—but many novel investigational agents are being studied to provide more efficacious, better tolerated therapies

Paul Y. Kwo, MD Released: August 2, 2022